DE69332605T2 - Allosterische modulatoren des nmda-rezeptors - Google Patents

Allosterische modulatoren des nmda-rezeptors

Info

Publication number
DE69332605T2
DE69332605T2 DE69332605T DE69332605T DE69332605T2 DE 69332605 T2 DE69332605 T2 DE 69332605T2 DE 69332605 T DE69332605 T DE 69332605T DE 69332605 T DE69332605 T DE 69332605T DE 69332605 T2 DE69332605 T2 DE 69332605T2
Authority
DE
Germany
Prior art keywords
nmda receptor
allosteric modulators
allosteric
modulators
nmda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332605T
Other languages
English (en)
Other versions
DE69332605D1 (de
Inventor
Maria-Luisa Maccecchini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69332605D1 publication Critical patent/DE69332605D1/de
Application granted granted Critical
Publication of DE69332605T2 publication Critical patent/DE69332605T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Peptides Or Proteins (AREA)
DE69332605T 1992-09-28 1993-09-28 Allosterische modulatoren des nmda-rezeptors Expired - Fee Related DE69332605T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95281892A 1992-09-28 1992-09-28
PCT/US1993/009295 WO1994007914A1 (en) 1992-09-28 1993-09-28 Allosteric modulators of the nmda receptor

Publications (2)

Publication Number Publication Date
DE69332605D1 DE69332605D1 (de) 2003-02-06
DE69332605T2 true DE69332605T2 (de) 2003-05-08

Family

ID=25493263

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332605T Expired - Fee Related DE69332605T2 (de) 1992-09-28 1993-09-28 Allosterische modulatoren des nmda-rezeptors

Country Status (8)

Country Link
US (1) US5830998A (de)
EP (1) EP0625988B1 (de)
JP (1) JPH07505908A (de)
AU (1) AU680448B2 (de)
CA (1) CA2124566A1 (de)
DE (1) DE69332605T2 (de)
ES (1) ES2188596T3 (de)
WO (1) WO1994007914A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6515103B1 (en) 1996-07-22 2003-02-04 University Of Utah Research Foundation Conantokins
WO1998003189A1 (en) * 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
US6624288B1 (en) * 1997-12-16 2003-09-23 Cognetix, Inc. Gamma-conopeptides
WO1999040436A1 (en) * 1998-02-10 1999-08-12 University Of Utah Research Foundation METHODS FOR PURIFYING AND ASSAYING A CONUS η-CARBOXYLASE
CA2386555A1 (en) * 1999-09-10 2001-03-15 University Of Utah Research Foundation Gamma-carboxyglutamate containing conopeptides
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
AU2001296389A1 (en) * 2000-09-29 2002-04-08 Cognetix, Inc. Stable peptide formulations
AU2002248553A1 (en) * 2001-03-07 2002-09-24 Cognetix, Inc Linear y-carboxyglutamate rich conotoxins
NZ531785A (en) * 2001-08-20 2007-03-30 Maiken Nedergaard Treatment of glial tumors with ionotropic glutamate receptor antagonists
EP1298581A1 (de) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Verfahren und Anlage zum Berechnen von Neuronenwerten in einem neuronalen Netzwerk
EP1476178A4 (de) * 2002-02-14 2009-08-26 Bayer Pharmaceuticals Corp Formulierungsstrategien zur stabilisierung von peptiden in organischen lösungsmitteln und in getrockneten zuständen
WO2010093070A1 (ko) * 2009-02-12 2010-08-19 서울대학교산학협력단 Glur2-결손 ampar 길항제를 포함하는 정신 질환 예방 또는 치료용 약학 조성물
CN102167730A (zh) * 2011-01-29 2011-08-31 浙江大学 芋螺毒素类似物Glu-Con-G[1-13]、设计合成方法及用途
WO2017109756A2 (es) * 2015-12-22 2017-06-29 Universidad Nacional De Colombia Péptidos sintéticos moduladores del receptor nmda

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1417736A (fr) * 1963-12-17 1965-11-12 Asahi Chemical Ind Procédé pour réaliser la synthèse de l'alpha-aminoglutaronitrile, de l'acide dl-glutamique, et de leurs dérivés alcoylés
US3658968A (en) * 1970-06-11 1972-04-25 Merck & Co Inc Composition and method of treatment
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
ATE70535T1 (de) * 1986-02-13 1992-01-15 Ciba Geigy Ag Ungesaettigte aminosaeuren.
US5175344A (en) * 1986-02-13 1992-12-29 Ciba-Geigy Corporation Unsaturated amino acids
US5051413A (en) * 1986-02-13 1991-09-24 Ciba-Geigy Corporation Unsaturated amino acids
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
CA1305177C (en) * 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US5242947A (en) * 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
JP2757960B2 (ja) * 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
US5049555A (en) * 1988-12-19 1991-09-17 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid receptors as neuroprotectants and anxiolytics
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
JP2780115B2 (ja) * 1989-07-24 1998-07-30 旭化成工業株式会社 虚血性脳細胞障害に対する細胞保護剤
US6017957A (en) * 1989-08-08 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents
WO1991002523A1 (en) * 1989-08-17 1991-03-07 The Children's Medical Center Corporation Glutamatergic amino acid agonists and antagonists
US5189020A (en) * 1989-11-22 1993-02-23 Neurex Corporation Method of reducing neuronal damage using omega conotoxin peptides
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
DK101290D0 (da) * 1990-04-24 1990-04-24 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
GB9109007D0 (en) * 1991-04-26 1991-06-12 Merck Sharp & Dohme Therapeutic method
EP0518818A3 (en) * 1991-06-11 1993-04-28 Ciba-Geigy Ag Arylethers, their manufacture and use as medicament
JP3218038B2 (ja) * 1991-09-09 2001-10-15 ワーナー−ランバート・コンパニー 尿酸排泄促進剤およびｅａａ拮抗剤の組合せのための医薬組成物
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage

Also Published As

Publication number Publication date
WO1994007914A1 (en) 1994-04-14
JPH07505908A (ja) 1995-06-29
EP0625988A4 (de) 1998-03-04
CA2124566A1 (en) 1994-04-14
US5830998A (en) 1998-11-03
EP0625988A1 (de) 1994-11-30
ES2188596T3 (es) 2003-07-01
DE69332605D1 (de) 2003-02-06
AU680448B2 (en) 1997-07-31
AU5294593A (en) 1994-04-26
EP0625988B1 (de) 2003-01-02

Similar Documents

Publication Publication Date Title
DE59610558D1 (de) Stativ
FI935175A0 (fi) Tyrosinkinas- HER4-humanreceptor
DE69316016T2 (de) Durchflussmesser
NO973051L (no) Frakoblbart stigerör
DE69332182D1 (de) Entwicklerbehälter
DE69332605T2 (de) Allosterische modulatoren des nmda-rezeptors
DE69420988T2 (de) Zahnärztliche Ausgabeeinrichtung
DK46595A (da) Vibrator
DE69613737T2 (de) Vibrationsgerät
DE69209268D1 (de) Elektrophotographisches Farbgerät
DE69316781T2 (de) Elektrophotographisches Gerät
DE69310370D1 (de) Strömungsmesser
DE69618529D1 (de) Gegentaktmodulator
DE69316307T2 (de) Vibrator
DE69427178D1 (de) Modulatoren
DE59602001D1 (de) Puderbestäubungseinrichtung
ATA82892A (de) Interferometer
FI921646A0 (fi) Väripastan annostelulaite
DE59200814D1 (de) Abdeckvorrichtung für eckige Aussparungen verfliester Wände.
KR940020692U (ko) 분말체의 정량 유출장치
KR970045439U (ko) 시계의 기준 접점 기구
FI1995U1 (fi) Madrass
FI1994U1 (fi) Madrass
KR960030383U (ko) 등미는 손
KR970019172U (ko) 시계의 진동장치

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee